A retrospective study comparing the outcomes of lenvatinib plus PEMBRO versus lenvatinib monotherapy in patients with unresectable HCC in the real world setting
Latest Information Update: 20 Jul 2021
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 20 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology